A Phase II, Open Label, Uncontrolled and Multicenter Trial of Pazopanib Given as a Single Agent in Patients With Progressive Advanced/Metastatic Neuroendocrine Tumors (NET): a Search for Activity, Safety, and Predictive Biomarkers.

Trial Profile

A Phase II, Open Label, Uncontrolled and Multicenter Trial of Pazopanib Given as a Single Agent in Patients With Progressive Advanced/Metastatic Neuroendocrine Tumors (NET): a Search for Activity, Safety, and Predictive Biomarkers.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Neuroendocrine tumours
  • Focus Biomarker; Therapeutic Use
  • Acronyms PAZONET
  • Most Recent Events

    • 17 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 29 Sep 2015 Interim data expected by the end of 2015, as per Oxigene media release.
    • 19 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top